Ken Griffin Cv Rx, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$6.49 - $19.2 $40,887 - $120,960	-6,300 Reduced 41.18%	9,000 $107,000
Q1 2024 May 15, 2024	SELL	$17.99 - $30.49 $163,709 - $277,459	-9,100 Reduced 37.3%	15,300 $278,000
Q4 2023 Feb 14, 2024	SELL	$11.67 - $33.01 $212,394 - $600,782	-18,200 Reduced 42.72%	24,400 $767,000
Q3 2023 Nov 14, 2023	BUY	$13.56 - $18.47 $63,732 - $86,809	4,700 Added 12.4%	42,600 $646,000
Q2 2023 Aug 14, 2023	SELL	$8.57 - $15.44 $392,506 - $707,152	-45,800 Reduced 54.72%	37,900 $585,000
Q1 2023 May 15, 2023	BUY	$7.08 - $19.4 $480,732 - $1.32 Million	67,900 Added 429.75%	83,700 $780,000
Q4 2022 Feb 14, 2023	BUY	$8.94 - $18.35 $141,252 - $289,930	15,800 New	15,800 $289,000

13.5M

49.9K

2.1K

Ticker CVRX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 20,576,200
Market Cap $179M
Description
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The co...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.